Manoj Maniar
Overview
Explore the profile of Manoj Maniar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
White M, Babayeva M, Taft D, Maniar M
J Pharm Pharmacol
. 2013 Jun;
65(7):960-9.
PMID: 23738723
Objectives: Rigosertib (ON 01910.Na, Estybon) is a novel, anticancer agent undergoing phase 3 clinical trials for a lead indication against myelodysplastic syndromes (MDS). In this research, the permeability of rigosertib...
12.
Tamhane M, Maniar M, Ren C, Benzeroual K, Taft D
J Pharm Sci
. 2012 Dec;
102(2):732-40.
PMID: 23212688
ON 01210.Na (Ex-RAD) is a novel benzyl styryl sulfone analog, developed as a radioprotectant by Onconova Therapeutics Inc. The objectives of this research were to evaluate the hepatobiliary disposition of...
13.
Ghosh S, Kulkarni S, Perkins M, Hieber K, Pessu R, Gambles K, et al.
J Radiat Res
. 2012 Jul;
53(4):526-36.
PMID: 22843617
The aim of the present study was to assess recovery from hematopoietic and gastrointestinal damage by Ex-RAD(®), also known as ON01210.Na (4-carboxystyryl-4-chlorobenzylsulfone, sodium salt), after total body radiation. In our...
14.
Suman S, Datta K, Doiron K, Ren C, Kumar R, Taft D, et al.
J Radiat Res
. 2012 Jun;
53(3):368-76.
PMID: 22739006
ON 01210.Na (Ex-RAD), a chlorobenzylsulfone derivative was investigated for its pharmacologic and radioprotective properties when administered via oral and subcutaneous (SC) routes. The goals of the study were to assess...
15.
Olnes M, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, et al.
Leuk Res
. 2012 Apr;
36(8):982-9.
PMID: 22524974
Background: We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS). "Knockdown"...
16.
Ma W, Messersmith W, Dy G, Weekes C, Whitworth A, Ren C, et al.
Clin Cancer Res
. 2012 Feb;
18(7):2048-55.
PMID: 22338014
Purpose: Rigosertib, a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K), and gemcitabine have synergistic antitumor activity when combined in preclinical studies. This phase I...
17.
Suman S, Maniar M, Fornace Jr A, Datta K
Radiat Oncol
. 2012 Jan;
7:6.
PMID: 22264334
Background: Ionizing radiation-induced hematopoietic injury could occur either due to accidental exposure or due to diagnostic and therapeutic interventions. Currently there is no approved drug to mitigate radiation toxicity in...
18.
Chun A, Freshwater R, Taft D, Gillum A, Maniar M
Biopharm Drug Dispos
. 2011 Feb;
32(2):99-111.
PMID: 21341279
ON 01210.Na (Ex-RAD®) is a novel small molecule under development by Onconova Therapeutics, Inc. as a radiation protection agent. The purpose of this investigation was to evaluate the effect of...
19.
Chun A, Cosenza S, Taft D, Maniar M
Cancer Chemother Pharmacol
. 2009 May;
65(1):177-86.
PMID: 19466411
Purpose: ON 01910.Na is a novel targeted anti-cancer agent under clinical investigation in Phase I and II trials. The purpose of this research was to evaluate the pharmacokinetic profile of...
20.
Ghosh S, Perkins M, Hieber K, Kulkarni S, Kao T, Reddy E, et al.
Radiat Res
. 2009 Mar;
171(2):173-9.
PMID: 19267542
Ex-Rad is among a series of small molecule kinase inhibitors developed for modifying cell cycle distribution patterns in cancer cells subjected to radiation therapy, and it has been identified as...